Resection for thoracic metastases from sarcoma.
Sarcoma metastasizes to the lungs in 20% to 40% of patients and in most cases does not involve any other organ. Systemic chemotherapy is of unproven benefit for stage IV sarcoma. Retrospective studies have shown 5-year survival rates of 21% to 38% with wedge resection of metastatic pulmonary nodules, and up to 30% to 40% of patients survive an additional 5 years with repeated metastasectomy. In this article, we provide an extensive review of patient selection criteria and surgical approaches, as well as of controversies regarding resection for metastatic sarcoma.
Division of Thoracic Surgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Zachary
Z
Kon
Linda
L
Martin
D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D008197:Lymph Node Excision; D059146:Metastasectomy / Q000379:methods*; D064847:Multimodal Imaging / Q000379:methods; D018579:Patient Selection; D049268:Positron-Emission Tomography; D011300:Preoperative Care; D012509:Sarcoma / Q000556:secondary*; D014057:Tomography, X-Ray Computed